A major milestone has been reached in the Republic of Ireland’s newborn health programme, as testing for Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID) is now officially underway.
From today, all babies undergoing the National Newborn Bloodspot Screening Programme in the Republic of Ireland, commonly known as the heel prick test, will be screened for these two serious but treatable conditions. This brings the total number of conditions screened at birth to 11.
Announcing the expansion, Minister for Health Jennifer Carroll MacNeill described the move as a “significant milestone” for families across Ireland. Early detection, she noted, allows for timely intervention and can dramatically improve outcomes for affected children.
The programme is expected to identify approximately six to seven babies with SMA and one to two babies with SCID each year. According to Dr Abigail Collins, HSE National Clinical Lead for Child Health Public Health, this early diagnosis will enable faster access to treatment and better long-term outcomes.
For families and advocates, the announcement marks the culmination of years of campaigning. Jonathan O’Grady, Director of SMA Ireland, called it a “truly historic day,” highlighting the life-changing impact that early detection can have for babies born with SMA.
The Minister also confirmed that work is already underway to explore further expansions to the screening programme, as part of Ireland’s ongoing commitment to improving care for those affected by rare diseases.
